Compare Amphastar Pharmaceuticals Inc (AMPH) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs VanEck Vietnam ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while VanEck Vietnam ETF trades at $17.61. The key difference: VanEck Vietnam ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | VNM | |
|---|---|---|
Market Cap | $863.95M | — |
Sector | Health | Sector/Thematic |
52-Week High | $30.81 | $19.80 |
52-Week Low | $16.87 | $16.34 |
Enterprise Value | $1.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
VNM trades at $17.44, showing minimal daily change. Technical indicators are bullish overall, with moving averages signaling strength, while oscillators remain neutral. Key support and resistance levels are tightly clustered around $17 and $18. Recent news highlights regional capital flows and Vietnam-specific challenges, including power grid strain and FTSE Russell's emerging market reclassification affecting the ETF's performance.
The outlook is mixed, with technical strength countered by fundamental data gaps and external risks. Investment opportunity hinges on Vietnam's economic trajectory and foreign investment inflows, but risks include macroeconomic pressures and domestic infrastructure issues. Clarity on financial metrics is essential for a complete assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
